PDF(Pubmed)
Abstract：
Chimeric antigen receptor T cell (CAR-T) therapy, an innovative immune cell therapy, has revolutionized the treatment landscape of haematological malignancies. The past 2 years has witnessed the successful application of CD19-targeting CAR constructs in refractory cases of autoimmune rheumatic diseases, including systemic lupus erythematosus, systemic sclerosis and anti-synthetase syndrome. In comparison with existing B cell depletion therapies, targeting CD19 has demonstrated a more rapid and profound therapeutic effect, enabling drug-free remission with manageable adverse events. These promising results necessitate validation through long-term, large-sample randomized controlled studies. Corroborating the role of CAR-T therapy in refractory rheumatological disorders and affirming safety, efficacy and durability of responses are the aims of future clinical studies. Optimizing the engineering strategies and better patient selection are also critical to further refining the successful clinical implementation of CAR-T therapy.
摘要：
嵌合抗原受体T细胞(CAR-T)治疗,一种创新的免疫细胞疗法，彻底改变了血液恶性肿瘤的治疗领域。在过去的两年中，CD19靶向CAR构建体在自身免疫性风湿性疾病的难治性病例中的成功应用。包括系统性红斑狼疮,系统性硬化症,和抗合成酶综合征.与现有的B细胞耗竭疗法相比，靶向CD19已经证明了更快速和深远的治疗效果，使无药物缓解和可控制的不良事件。这些有希望的结果需要通过长期的验证，大样本,随机对照研究。证实CAR-T疗法在难治性风湿病中的作用，并确认安全性，反应的有效性和持久性是未来临床研究的目标。优化工程策略和更好的患者选择对于进一步完善CAR-T疗法的成功临床实施也至关重要。
